

Table II. *Clinical features and treatment outcomes of seven non-seminomatous patients.*

Case no.	Age	Histology (biopsy)	Histology (resection/autopsy)	Histology (excision biopsy of metastatic site)	CTx	AFP (ng/ml)	HCG (IU/l)	LDH (IU/l)	Course	Observation period (months)	Outcome
1	19	Y	IT	Undifferentiated sarcomatous components	BEP(4), VeIP(1), TIP(3), Paz	879	1720	750	PD	94	AD
2	20	IT+Y	IT+Y	ND	BEP(8), VIP(4), HDCT(2), TIP(2), CPT-11/N(3)	1254	N/A	<230	Elevation of HCG	61	Dead
3	18	Y+T with malignant	AML	ND	BEP(4)	3307	N/A	391	CR	6	Dead
4	31	Y	Viable cell(-)	ND	BEP(4), HDCT(2)	188530	N/A	<230	PRm-	200	NED
5	21	Y+ sarcomatous area	IT	Spindle and pleomorphic cell sarcoma	BEP(4), ADM(8), Paz	2928	169	202	PRm+	61	AD
6	25	Suggestive of T	HS	ND	BEP(3), TIP(1), VeIP(1)	269.6	N/A	174	PRm-	9	Dead
7	31	EC+T	AML	ND	BEP(4), IDR + Ara-C	1178	7.4	308	CR	6.5	Dead

AD: Alive with disease; ADM: doxorubicin; AFP: alpha fetoprotein; AML: acute megakaryocytic leukemia; BEP: bleomycin, etoposide, cisplatin; CPT-11/N: irinotecan, nedaplatin; CR: complete remission; CTx: chemotherapy; EC: embryonal carcinoma; HDCT: high-dose chemotherapy; HCG: human chorionic gonadotropin; HS: histiocytic sarcoma; IDR+Ara-C: idarubicin + cytar-abine; IT: immature teratoma; LDH: lactate dehydrogenase; N/A: not available; ND: not done; NED: no evidence of disease; Paz: pazopanib; T: teratoma; TIP: paclitaxel, iphosphamide, cisplatin; VeIP: vinblastine, iphosphamide, cisplatin; VIP: etoposide, iphosphamide, cisplatin; Y: yolk sac tumor.